Avalyn Pharma said its inhaled perfenidone, APO1, completed enrollment in a large global Phase 2b study over the summer, with 52-week data expected in the second half of next year. Its base case is another Phase 3 study before approval. Inhaled nintetanib, APO2, has a 12-week proof-of-concept study with data expected late in 2027.
AVLN · Avalyn Pharma Inc. · Documents
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Avalyn Pharma reported a nine-month net loss of $85.5 million and $386.6 million in cash, cash equivalents and marketable securities as of September 30, 2026, which it expects to fund operations into 2029.
Avalyn Pharma Inc. started a Phase 1 study of AP03 in healthy volunteers. It had $386.6 million in cash, cash equivalents and marketable securities on September 30, 2026, with runway projected into 2029; third-quarter net loss was $29.7 million.
Avalon said around $400 million of cash extends its runway into 2029, assuming Phase 3 funding for AP01 and AP02. The inhaled profenidone MIST study enrolled 398 patients with progressive pulmonary fibrosis.